Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amicus Repositions With A Focus On Combining Chaperones With ERTs

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech re-obtains all rights to migalastat from GSK, buys out ERT specialist Callidus and will raise $40 million through a private placement and a debt financing. Callidus co-founder, a former Genzyme scientist, will take over the Amicus’ scientific team, while the company slashes its overall headcount by 14%.


Related Content

Persistence Pays Off For Amicus: Positive Migalastat Data In Hand
Still Hopeful About Migalastat, Amicus Also Pursuing Optimized Enzyme Replacement Therapies
Deals Of The Week Wonders: Will Pharma Ever Pay More For Companion Diagnostics?
Sanofi Claims Genzyme With $20.1 Billion Upfront And CVRs
Going Deeper Into Rare Disease, GSK Takes Reins of Amicus Fabry Program


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts